C4Diagnostics

C4Diagnostics, a biotechnology company founded in 2017 and headquartered in France, focuses on developing in vitro diagnostic tests for human infectious diseases. The company's approach is to create IVD tests that are faster than reference methods while ensuring comparable or superior performance. Its portfolio includes diagnostic tests for Covid-19 (C4Covid-19 Human), legionellosis (C4Legio-LFA), urinary tract infections (C4UTI), and antibiograms (C4AST). Additionally, C4Diagnostics has a Business Unit dedicated to environmental diagnostics (C4Environment), offering services for detecting SARS-CoV-2 and other pathogens in various environmental sources. The company has actively contributed to Covid-19 surveillance and prevention campaigns since the onset of the pandemic. C4Diagnostics aims to emerge as a key player in the human infectious disease diagnostics sector by providing healthcare professionals with rapid and reliable diagnostic information to enhance patient care. The diagnostic solutions developed by C4Diagnostics serve as a lever to combat antibiotic resistance and halt infectious disease epidemics. Notably, the last investment of €2.30M in a Venture Round was secured on 24 January 2020 from investors including Région Sud Investissement, Andreï Polukhtin, R2V, and CAAP Creation. For further inquiries, C4Diagnostics can be reached at [email protected].